http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101387102-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-498 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61Q19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-185 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-97 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 |
| filingDate | 2012-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101387102-B1 |
| titleOfInvention | Crosslinking inhibitor of the final glycation end product containing disubstituted acid as an active ingredient and disintegrant |
| abstract | The present invention relates to a cross-linking inhibitor and a disintegrating pharmaceutical composition which contain a chelating acid as an active ingredient and inhibit cross-linking between the final glycation end product and the protein and to dissolve the cross-link formed. According to the present invention, it is possible to inhibit the structural change of proteins such as collagen and elastin in tissues because it inhibits the cross-linking between the protein and the final glycation product, And the improvement of the disease caused by the disease can be reduced or cured. |
| priorityDate | 2012-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 50.